RT Journal Article
SR Electronic
T1 Researching COVID to enhance recovery (RECOVER) adult study protocol: Rationale, objectives, and design
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.05.26.23290475
DO 10.1101/2023.05.26.23290475
A1 Horwitz, Leora I.
A1 Thaweethai, Tanayott
A1 Brosnahan, Shari B.
A1 Cicek, Mine S.
A1 Fitzgerald, Megan L.
A1 Goldman, Jason D.
A1 Hess, Rachel
A1 Hodder, S. L.
A1 Jacoby, Vanessa L.
A1 Jordan, Michael R.
A1 Krishnan, Jerry A.
A1 Laiyemo, Adeyinka O.
A1 Metz, Torri D.
A1 Nichols, Lauren
A1 Patzer, Rachel E.
A1 Sekar, Anisha
A1 Singer, Nora G.
A1 Stiles, Lauren E.
A1 Taylor, Barbara S.
A1 Ahmed, Shifa
A1 Algren, Heather A.
A1 Anglin, Khamal
A1 Aponte-Soto, Lisa
A1 Ashktorab, Hassan
A1 Bassett, Ingrid V.
A1 Bedi, Brahmchetna
A1 Bhadelia, Nahid
A1 Bime, Christian
A1 Bind, Marie-Abele C.
A1 Black, Lora J.
A1 Blomkalns, Andra L.
A1 Brim, Hassan
A1 Castro, Mario
A1 Chan, James
A1 Charney, Alexander W.
A1 Chen, Benjamin K.
A1 Chen, Li Qing
A1 Chen, Peter
A1 Chestek, David
A1 Chibnik, Lori B.
A1 Chow, Dominic C.
A1 Chu, Helen Y.
A1 Clifton, Rebecca G.
A1 Collins, Shelby
A1 Costantine, Maged M.
A1 Cribbs, Sushma K.
A1 Deeks, Steven G.
A1 Dickinson, John D.
A1 Donohue, Sarah E.
A1 Durstenfeld, Matthew S.
A1 Emery, Ivette F.
A1 Erlandson, Kristine M.
A1 Facelli, Julio C.
A1 Farah-Abraham, Rachael
A1 Finn, Aloke V.
A1 Fischer, Melinda S.
A1 Flaherman, Valerie J.
A1 Fleurimont, Judes
A1 Fonseca, Vivian
A1 Gallagher, Emily J.
A1 Gander, Jennifer C.
A1 Gennaro, Maria Laura
A1 Gibson, Kelly S.
A1 Go, Minjoung
A1 Goodman, Steven N.
A1 Granger, Joey P.
A1 Greenway, Frank L.
A1 Hafner, John W.
A1 Han, Jenny E.
A1 Harkins, Michelle S.
A1 Hauser, Kristine S.P.
A1 Heath, James R.
A1 Hernandez, Carla R.
A1 Ho, On
A1 Hoffman, Matthew K.
A1 Hoover, Susan E.
A1 Horowitz, Carol R.
A1 Hsu, Harvey
A1 Hsue, Priscilla Y.
A1 Hughes, Brenna L.
A1 Jagannathan, Prasanna
A1 James, Judith A.
A1 John, Janice
A1 Jolley, Sarah
A1 Judd, S. E.
A1 Juskowich, Joy J.
A1 Kanjilal, Diane G.
A1 Karlson, Elizabeth W.
A1 Katz, Stuart D.
A1 Kelly, J. Daniel
A1 Kelly, Sara W.
A1 Kim, Arthur Y.
A1 Kirwan, John P.
A1 Knox, Kenneth S.
A1 Kumar, Andre
A1 Lamendola-Essel, Michelle F.
A1 Lanca, Margaret
A1 Lee-lannotti, Joyce K.
A1 Lefebvre, R. Craig
A1 Levy, Bruce D.
A1 Lin, Janet Y.
A1 Logarbo, Brian P.
A1 Logue, Jennifer K.
A1 Longo, Michele T.
A1 Luciano, Carlos A.
A1 Lutrick, Karen
A1 Malakooti, Shahdi K.
A1 Mallett, Gail
A1 Maranga, Gabrielle
A1 Marathe, Jai G.
A1 Marconi, Vincent C.
A1 Marshall, Gailen D.
A1 Martin, Christopher F.
A1 Martin, Jeffrey N.
A1 May, Heidi T.
A1 McComsey, Grace A.
A1 McDonald, Dylan
A1 Mendez-Figueroa, Hector
A1 Miele, Lucio
A1 Mittleman, Murray A.
A1 Mohandas, Sindhu
A1 Mouchati, Christian
A1 Mullington, Janet M.
A1 Nadkarni, Girish N
A1 Nahin, Erica R.
A1 Neuman, Robert B.
A1 Newman, Lisa T.
A1 Nguyen, Amber
A1 Nikolich, Janko Z.
A1 Ofotokun, Igho
A1 Ogbogu, Princess U.
A1 Palatnik, Anna
A1 Palomares, Kristy T.S.
A1 Parimon, Tanyalak
A1 Parry, Samuel
A1 Parthasarathy, Sairam
A1 Patterson, Thomas F.
A1 Pearman, Ann
A1 Peluso, Michael J.
A1 Pemu, Priscilla
A1 Pettker, Christian M.
A1 Plunkett, Beth A.
A1 Pogreba-Brown, Kristen
A1 Poppas, Athena
A1 Porterfield, J. Zachary
A1 Quigley, John G.
A1 Quinn, Davin K.
A1 Raissy, Hengameh
A1 Rebello, Candida J.
A1 Reddy, Uma M.
A1 Reece, Rebecca
A1 Reeder, Harrison T.
A1 Rischard, Franz P.
A1 Rosas, Johana M.
A1 Rosen, Clifford J.
A1 Rouphael, Nadine G.
A1 Rouse, Dwight J.
A1 Ruff, Adam M.
A1 Jean, Christina Saint
A1 Sandoval, Grecio J.
A1 Santana, Jorge L.
A1 Schlater, Shannon M.
A1 Sciurba, Frank C.
A1 Selvaggi, Caitlin
A1 Seshadri, Sudha
A1 Sesso, Howard D.
A1 Shah, Dimpy P.
A1 Shemesh, Eyal
A1 Sherif, Zaki A.
A1 Shinnick, Daniel J.
A1 Simhan, Hyagriv N.
A1 Singh, Upinder
A1 Sowles, Amber
A1 Subbian, Vignesh
A1 Sun, Jun
A1 Suthar, Mehul S.
A1 Teunis, Larissa J.
A1 Thorp, John M.
A1 Ticotsky, Amberly
A1 Tita, Alan T. N.
A1 Tragus, Robin
A1 Tuttle, Katherine R.
A1 Urdaneta, Alfredo E.
A1 Utz, P. J.
A1 VanWagoner, Timothy M.
A1 Vasey, Andrew
A1 Vernon, Suzanne D.
A1 Vidal, Crystal
A1 Walker, Tiffany
A1 Ward, Honorine D.
A1 Warren, David E.
A1 Weeks, Ryan M.
A1 Weiner, Steven J.
A1 Weyer, Jordan C.
A1 Wheeler, Jennifer L.
A1 Whiteheart, Sidney W.
A1 Wiley, Zanthia
A1 Williams, Natasha J.
A1 Wisnivesky, Juan P.
A1 Wood, John C.
A1 Yee, Lynn M.
A1 Young, Natalie M.
A1 Zisis, Sokratis N.
A1 Foulkes, Andrea S.
YR 2023
UL http://medrxiv.org/content/early/2023/05/28/2023.05.26.23290475.abstract
AB Importance SARS-CoV-2 infection can result in ongoing, relapsing, or new symptoms or other health effects after the acute phase of infection; termed post-acute sequelae of SARS-CoV-2 infection (PASC), or long COVID. The characteristics, prevalence, trajectory and mechanisms of PASC are ill-defined. The objectives of the Researching COVID to Enhance Recovery (RECOVER) Multi-site Observational Study of PASC in Adults (RECOVER-Adult) are to: (1) characterize PASC prevalence; (2) characterize the symptoms, organ dysfunction, natural history, and distinct phenotypes of PASC; (3) identify demographic, social and clinical risk factors for PASC onset and recovery; and (4) define the biological mechanisms underlying PASC pathogenesis.Methods RECOVER-Adult is a combined prospective/retrospective cohort currently planned to enroll 14,880 adults aged ≥18 years. Eligible participants either must meet WHO criteria for suspected, probable, or confirmed infection; or must have evidence of no prior infection. Recruitment occurs at 86 sites in 33 U.S. states, Washington, DC and Puerto Rico, via facility– and community-based outreach. Participants complete quarterly questionnaires about symptoms, social determinants, vaccination status, and interim SARS-CoV-2 infections. In addition, participants contribute biospecimens and undergo physical and laboratory examinations at approximately 0, 90 and 180 days from infection or negative test date, and yearly thereafter. Some participants undergo additional testing based on specific criteria or random sampling. Patient representatives provide input on all study processes. The primary study outcome is onset of PASC, measured by signs and symptoms. A paradigm for identifying PASC cases will be defined and updated using supervised and unsupervised learning approaches with cross– validation. Logistic regression and proportional hazards regression will be conducted to investigate associations between risk factors, onset, and resolution of PASC symptoms.Discussion RECOVER-Adult is the first national, prospective, longitudinal cohort of PASC among US adults. Results of this study are intended to inform public health, spur clinical trials, and expand treatment options.Competing Interest StatementI have read the journal's policy and the authors of this manuscript have the following competing interests: Helen Chu reported consulting for Merck, GSK, Pfizer, Ellume, Janssen, Vindico CME, and the Bill and Melinda Gates Foundation, and receiving research support from Gates Ventures, Ellume, and Sanofi Pasteur. She also serves as a co-investigator on studies funded by Pfizer, Novavax, and GSK. Maged Costantine reported receiving grant support for work not related to RECOVER work/publications from Baxter International and Siemens Healthcare and personal consulting fees not related to this paper from Progenity, Quidel Ortho, and Siemens Healthcare. Kristine Erlandson reported research funding from Gilead Sciences and consulting payments from Gilead Sciences, Merck, and ViiV Pharmaceuticals, all paid to the University of Colorado. Emily Gallagher reported consulting for Novartis, Flare Therapeutics and Seagen. Edward Gardner reported research support (clinical trials) from Gilead Sciences, ViiV Healthcare, and Cepheid. Jason Goldman reported research support from Gilead, Eli Lilly and Regeneron; grants from Gilead, Merck (BARDA); personal fees for consulting from Gilead, Eli Lilly; and non-financial support from Adaptive Biotechnologies and Labcorp/Monogram Biosciences outside the submitted work. Timothy Heinrich reported grant support from Merck Inc. and consulting fees from Roche. Rachel Hess reported serving as Data Safety Monitoring Board member for Astellas Pharmaceuticals unrelated to the current work. Leora Horwitz reported being a member of the National Academy of Medicine Committee on the Long-Term Health Effects Stemming from COVID-19 and Implications for the Social Security Administration. Priscilla Hsue reported receiving honoraria from Gilead and Merck unrelated to study topic, receiving study drug from Regeneron unrelated to study topic, and receiving a research grant from Novartis. Judith James reported OMRF has licensed her IP to Progentec Biosciences, has received grant support from Progentec Biosciences, and serves on Advisory Committees to Glaxo Smith Klein, Merck and Novartis. Arthur Kim reports providing educational materials to Clinical Care Options and UpToDate and serving on a Data Safety Monitoring board for Kintor Pharmaceuticals, Ltd. Bruce Levy reported serving as a consultant for AstraZeneca, Entrinsic Biosciences, Gossamer Bio and Nocion Therapeutics and receiving research support from Amgen, Genentech, GlaxoSmithKline, Pieris Pharmaceuticals, SRA and Sanofi unrelated to the current work. Vincent Marconi reported receiving grants from NIH during the conduct of the study and grants from NIH, Veteran Affairs, and Centers for Disease Control and Prevention; grants, personal fees, nonfinancial support, and other from Lilly and Gilead; grants and personal fees from ViiV; and nonfinancial support from Bayer outside the submitted work. Grace McComsey reported serving as consultant for Merck, Gilead, ViiV, Janssen and have received research support from Pfizer, Vanda, Genentech, Roche, Redhill and Cognivue. Torri Metz reported being a site PI and a participant in the medical advisory board for the planning of a Pfizer clinical trial of SARS-CoV-2 vaccination in pregnancy. She also reported being a site PI for a Pfizer study evaluating the pharmacokinetics of Paxlovid in pregnant people with COVID-19. Janet Mullington reported support for investigator-initiated research by "Open Medicine Foundation and the Patient-Led Research Collaborative" Princess Ogbogu reported research support from Astrazeneca, GSK, Blueprint medical; advisory board for Astrazeneca, GSK, Sanofi, Kalvista; and consulting for Astrazeneca, GSK. Sairam Parthasarathy reported research funding to Institution from Sergey Brin foundation of COVID and Long-COVID research. Michael Peluso reported consulting fees from Gilead Sciences and AstraZeneca, and service on data safety monitoring board for American Gene Technologies. Sean Quigley reported service on speaker Board for Servier, Alnylam, Agios; service on advisory board for Recordati, Alexion. Franz Rischard reported research support from NIH/NHLBI, United Therapeutics, Acceleron/Merck, Janssen, Insmed, Aerovate, and Bayer; and consulting/advisory compensation from Acceleron and Bayer. Nadine Rouphael reported being a consultant for ICON and EMMES as a safety consultant for clinical trials; service on the advisory boards for Moderna; funds to institution from Sanofi, Lilly, Merck, Quidel and Pfizer. PJ Utz reported stock ownership of Gilead and PI of biomarker studies for Pfizer STOP-PASC paxlovid trial. Juan Wisnivesky received receiving consulting honorarium from Sanofi, Banook, Prospero, PPD and Atea and research grants from Sanofi, Regeneron, Axella, and Arnold Consultants.Clinical Protocols https://recovercovid.org/sites/default/files/docs/Adult.Protocol.v7.0.pdf Funding StatementThe research was funded by the National Institutes of Health (NIH) Agreement OTA OT2HL161847 as part of the Researching COVID to Enhance Recovery (RECOVER) research Initiative.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:IRB of NYU Grossman School of Medicine gave ethical approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesNo datasets were generated or analysed during the current study. All relevant data from this study will be made available upon study completion.